Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Menarini Launches PE Drug in UK | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances, Trials & Filings

Menarini Launches PE Drug in UK

Triggers milestone payment to Furiex

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The Menarini Group has launched Priligy, an on-demand treatment of premature ejaculation, in the UK. Priligy is marketed for that indication in more than 20 countries in Europe, Asia and Latin America, and is approved for that indication in more than 60 countries worldwide.

The UK launch triggered a $5.0 million milestone payment from Menarini to Furiex Pharmaceuticals, Inc. (FURX), a drug development collaboration company. In May 2012, Furiex entered into a license agreement with Menarini to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East. Under the terms of the license agreement, Furiex is eligible to as much as $40.0 million in sales-based milestones, plus tiered royalties ranging from the mid-teens to mid-twenties in percentage terms.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics